Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.50 Consensus Target Price from Analysts

Tyra Biosciences, Inc. (NASDAQ:TYRA) has earned a consensus recommendation of “Buy” from the six research firms that are presently covering the company, MarketBeat Ratings reports. Six research analysts have rated the stock with a buy rating. The average twelve-month price objective among analysts that have covered the stock in the last year is $30.50.

A number of brokerages have recently issued reports on TYRA. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Tuesday, February 18th. UBS Group assumed coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 target price on the stock.

Insider Transactions at Tyra Biosciences

In other news, Director Nina S. Kjellson sold 5,401 shares of the business’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total value of $74,317.76. Following the transaction, the director now directly owns 443,885 shares of the company’s stock, valued at $6,107,857.60. The trade was a 1.20 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In the last quarter, insiders have sold 21,998 shares of company stock valued at $344,818. 15.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Tyra Biosciences

A number of hedge funds and other institutional investors have recently bought and sold shares of TYRA. KLP Kapitalforvaltning AS acquired a new stake in shares of Tyra Biosciences in the fourth quarter valued at $31,000. US Bancorp DE bought a new stake in Tyra Biosciences during the 4th quarter worth about $50,000. BNP Paribas Financial Markets acquired a new stake in Tyra Biosciences in the 4th quarter valued at about $60,000. Aquatic Capital Management LLC bought a new position in shares of Tyra Biosciences in the fourth quarter worth about $64,000. Finally, Wells Fargo & Company MN lifted its position in shares of Tyra Biosciences by 51.7% during the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company’s stock worth $132,000 after purchasing an additional 3,236 shares in the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Trading Down 3.2 %

Shares of NASDAQ TYRA opened at $10.31 on Friday. The firm has a market capitalization of $521.72 million, a price-to-earnings ratio of -6.40 and a beta of 1.09. Tyra Biosciences has a one year low of $9.93 and a one year high of $29.60. The business has a fifty day simple moving average of $12.85 and a 200 day simple moving average of $16.54.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.